Table 1 Baseline characteristics of patients with severe HFMD caused by EV71 in the non-CVVHDF group and the CVVHDF group

Age, month

21.0 (8.3, 23.8)

23.0 (12.5, 24.0)

0.372

Male, n

8

10

0.717

Severity

0.979

 Stage 3, n

7

10

 Stage 4, n

5

7

Body weight, kg

10.6 (8.3, 14.4)

11.0 (10.0, 14.4)

0.565

Body temperature, °C

39.7 (39.4, 39.8)

39.7 (39.3, 40.0)

0.518

Heart rate, bpm

188 (171, 195)

187 (178, 198)

0.982

LVEF, %

38 (26, 44)

37 (24, 47)

0.773

CI, L/min/m²

2.89 (2.23,3.63)

2.73 (1.92, 3.95)

0.642

Systolic blood pressure, mmHg

132.0 (76.0, 150.5)

139 (102, 155)

0.116

Acute kidney injury, n

2

4

0.653

Fluid overload, n

3

6

0.694

Mechanical ventilator, n

12

17

/

 Milrinone, n

7

7

0.462

 Phentolamine, n

1

0

0.414

 Sodium nitroprusside, n

4

2

0.198

 Dopamine, n

4

6

0.913

 Dobutamine, n

9

13

1.000

 Norepinephrine, n

1

3

0.622

 Adrenaline, n

2

4

1.000